DOCSLIB.ORG

Update on the Mechanism of Action of Aripiprazole: Translational Insights Into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Update on the Mechanism of Action of Aripiprazole: Translational Insights Into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism CNS Drugs (2015) 29:773–799 DOI 10.1007/s40263-015-0278-3 REVIEW ARTICLE Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism 1 1 1 Andrea de Bartolomeis • Carmine Tomasetti • Felice Iasevoli Published online: 7 September 2015 Ó The Author(s) 2015. This article is published with open access at Springerlink.com Abstract Dopamine partial agonism and functional selec- novel and future biased ligand compounds. This review aims tivity have been innovative strategies in the pharmacological to recapitulate the main neurobiological effects of aripipra- treatment of schizophrenia and mood disorders and have zole and discuss the potential implications for upcoming shifted the concept of dopamine modulation beyond the improvements in schizophrenia therapy based on dopamine established approach of dopamine D2 receptor (D2R) antag- modulation beyond D2R antagonism. onism. Despite the fact that aripiprazole was introduced in therapy more than 12 years ago, many questions are still unresolved regarding the complexity of the effects of this Key Points agent on signal transduction and intracellular pathways, in part linked to its pleiotropic receptor profile. The complexity The atypical antipsychotic aripiprazole has a unique of the mechanism of action has progressively shifted the pharmacological profile that provides ‘adaptive’ conceptualization of this agent from partial agonism to pharmacological activity. functional selectivity. From the induction of early genes to Depending on endogenous dopamine levels and modulation of scaffolding proteins and activation of tran- signaling status, aripiprazole may act as a full scription factors, aripiprazole has been shown to affect mul- antagonist, a moderate antagonist, or a partial agonist tiple cellular pathways and several cortical and subcortical at dopamine D2 receptors (D2Rs), consistent with neurotransmitter circuitries. Growing evidence shows that, purported biased ligand pharmacology. beyond the consequences of D2R occupancy, aripiprazole has a unique neurobiology among available antipsychotics. The The efficacy of aripiprazole can be mainly attributed effect of chronic administration of aripiprazole on D2R to this combination of partial agonism/antagonism at affinity state and number has been especially highlighted, with D2Rs and serotonin 5-HT1A receptors, together with relevant translational implications for long-term treatment of antagonism at serotonin 5-HT2A receptors. psychosis. The hypothesized effects of aripiprazole on cell- However, the receptor profile of the compound is protective mechanisms and neurite growth, as well as the much more complex, and animal models have shown differential effects on intracellular pathways [i.e. extracellular that aripiprazole affects multiple cellular pathways signal-regulated kinase (ERK)] compared with full D2R and several cortical and subcortical neurotransmitter antagonists, suggest further exploration of these targets by circuitries and has an impact on gene expression distinct from other antipsychotics. & Andrea de Bartolomeis Based on the pharmacological and functional [email protected] characteristics of aripiprazole, a number of new 1 Unit of Treatment Resistant Psychosis, Laboratory of dopaminergic biased ligands are emerging as Molecular and Translational Psychiatry, Department of potential candidates for the treatment of psychosis, Neuroscience, University School of Medicine of Napoli potentially improving the ‘dopamine modulation’ ‘‘Federico II’’, Via Pansini, 5, Edificio n.18, 3rd floor, 80131 Naples, Italy features of the prototypical compound. 774 A. de Bartolomeis et al. 1 Introduction forms from full D2R antagonist antipsychotic agents. Furthermore, these effects could be of relevant interest in the onset of secondary antipsychotic treatment resistance, More than 40 years since its first enunciation, the dopa- i.e. the onset of treatment resistance after a successful mine dysregulation hypothesis of schizophrenia is still response to an antipsychotic drug. The purpose of this considered pivotal for the pathophysiology of the disorder, review is to provide a depiction and critical appraisal of the even if preclinical and clinical research has emphasized the molecular pharmacology of aripiprazole and its effects on contribution of signaling of other neurotransmitters, pri- neurobiology as a mainstay for future studies on novel marily the glutamatergic and the serotonergic neurotrans- molecular targets for antipsychotic effect. mitters [1]. In its simplest form, the dopaminergic For the literature search, we conducted multiple sear- hypothesis states that an increase in dopamine release in ches using the PubMed database, with no date constraints the striatum (possibly as a final consequence of multiple but limited to English language articles. receptor aberrant interactions) is associated with a reduced The overall strategy can be summarized in three main dopaminergic tone in the dorsal prefrontal cortex [2]. This sections corresponding to the aim of the review. An initial mechanistic interpretation is probably too reductionist, data search was conducted using the key terms ‘aripipra- particularly considering the complexity of the molecular zole’ AND ‘receptor’, ‘pharmacokinetics’, ‘D2 receptor’, neurobiology of schizophrenia, which has been recently ‘partial agonism’, ‘functional selectivity’, ‘PET’, ‘gene’, conceptualized as a disorder of synaptic plasticity [3–5] ‘dopamine partial agonists’, ‘rat’. A second search was and of aberrant connectomics [6]; however, dopamine conducted focusing on the following key words: ‘arip- aberrant function represents a major landmark for iprazole’ AND ‘immediate early genes’, ‘transcription schizophrenia, both for pathophysiology and for pharma- factors’, ‘c-fos’, ‘Arc’, ‘Homer’, ‘Zif’. A third search cological treatment. included ‘aripiprazole derivatives’, ‘quinolinone deriva- Multiple lines of evidence, from preclinical models to tives’ AND ‘dopamine partial agonism’, ‘ergot derivatives’ in vivo neuroimaging studies in humans, demonstrate an AND ‘dopamine partial agonism’, ‘dopamine partial ago- aberrant release of dopamine in the striatum of nists’ AND ‘clinical studies’, ‘dopamine partial agonists’ schizophrenia patients [7]. In this regard, dynamic studies AND ‘preclinical studies’. measuring the binding of 11C-raclopride to striatal dopa- A final PubMed search was conducted in March 2015 mine D2 receptors (D2Rs) and dopamine D3 receptors immediately before the latest version of this review, with (D3Rs) in schizophrenia patients and in normal controls no restriction except, again, the English language, using the after an acute amphetamine challenge have robustly term ‘aripiprazole’. The new preclinical articles that fitted demonstrated that schizophrenia is associated with higher the subject of the article were selected and included. dopamine release in the striatum, and that this aberrant The articles found were initially reviewed by title and release may correlate with positive symptoms [8]. abstract then examined for relevance; after irrelevant arti- In the context of the dopamine hypothesis, the com- cles were discarded, the reference lists of selected articles plexity of dopamine receptor function deserves special were used to identify additional studies. emphasis, considering that, until the introduction of arip- iprazole, all available antipsychotics were characterized by D2R blockade (albeit to different degrees), and compounds 2 Pharmacokinetic Properties of Aripiprazole devoid of D2R blockade were not found to have an effi- cacious antipsychotic action [9]. Aripiprazole has changed 2.1 Absorption and Distribution this view of antipsychotic action on dopamine signaling, introducing for the first time in the treatment of psychosis a The mean elimination half-life of aripiprazole is about 75 h clinically relevant mechanism based on D2R occupancy after oral administration and reaches 94 h for dehy- without D2R blockade. Beyond its peculiar action on droaripiprazole, its active metabolite. Steady-state con- D2Rs, preclinical and in vivo studies in humans have centrations are attained within 14 days of dosing. After demonstrated the differential effects of aripiprazole on tablet administration, peak plasma concentrations are dopamine signaling and on multiple transcriptional effec- reached within 3–5 h. Tablet bioavailability is 87 %, while tors compared with the action of antipsychotics with full plasma concentrations are higher for the oral solution for- antagonist action at D2Rs. These effects range from the mulation [10, 11]. Administration with food, particularly a selective induction of early genes to the modulation of high-fat meal, does not affect mean peak plasma concen- distinct scaffolding proteins and transcription factors and tration (Cmax) or the area under the plasma concentration– imply that the compound targets multiple cellular pathways time curve, while it delays mean time at maximum serum and affects several neurobiological functions in different concentration (Tmax) by approximately 3 h for aripiprazole. Update on the Mechanism of Action of Aripiprazole 775 Steady-state volume of distribution is high, indicating Japanese subjects was found to reduce the systemic clear- extensive extravascular distribution. At therapeutic con- ance of the antipsychotic by 30 and 50 % in CYP2D6 centrations, both aripiprazole and dehydroaripiprazole are extensive and intermediate metabolizers, respectively
Load more

Recommended publications
  • Binding Kinetics Calculations of the Inclusion of Some Benzoic Acid Derivatives and Paracetamol in Β CD Djamel Khatmi, Belgacem Bezzina, Stéphane Humbel
    Binding kinetics calculations of the inclusion of some benzoic acid derivatives and paracetamol in β CD Djamel Khatmi, Belgacem Bezzina, Stéphane Humbel To cite this version: Djamel Khatmi, Belgacem Bezzina, Stéphane Humbel. Binding kinetics calculations of the inclusion of some benzoic acid derivatives and paracetamol in β CD. Journal of Inclusion Phenomena and Macrocyclic Chemistry, Springer Verlag, 2020, 96 (3-4), pp.373-379. 10.1007/s10847-020-00976-1. hal-02922032 HAL Id: hal-02922032 https://hal.archives-ouvertes.fr/hal-02922032 Submitted on 25 Aug 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Binding kinetics calculations of the inclusion of some benzoic acid derivatives and paracetamol in β CD. Djamel Eddine Khatmi,a, b* Belgacem Bezzina, b, c Stéphane Humbel,a a- Aix Marseille University, CNRS, Centrale Marseille, iSm2, Marseille, France b- Laboratory of Computational Chemistry and Nanostructures, University of 08 May 45 Guelma, Algeria c- Research Center in Industrial Technology (CRTI), P.O.BOX 64, Chéraga 16014, Algiers, Algeria *corresponding author: [email protected] KEYWORDS: Cyclodextrin. Inclusion complexes. Molecular dynamic simulation. Binding Kinetics. Benzoic acid derivatives. Paracetamol. ABSTRACT This theoretical study is designed to identify the main driving forces of the inclusion of some benzoic acid (BA) derivatives as well as Paracetamol (ParCM) with β-cyclodextrin (β-CD) by computing the kinetics of binding.
    [Show full text]
  • Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
    processes Review Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development Outi M. H. Salo-Ahen 1,2,* , Ida Alanko 1,2, Rajendra Bhadane 1,2 , Alexandre M. J. J. Bonvin 3,* , Rodrigo Vargas Honorato 3, Shakhawath Hossain 4 , André H. Juffer 5 , Aleksei Kabedev 4, Maija Lahtela-Kakkonen 6, Anders Støttrup Larsen 7, Eveline Lescrinier 8 , Parthiban Marimuthu 1,2 , Muhammad Usman Mirza 8 , Ghulam Mustafa 9, Ariane Nunes-Alves 10,11,* , Tatu Pantsar 6,12, Atefeh Saadabadi 1,2 , Kalaimathy Singaravelu 13 and Michiel Vanmeert 8 1 Pharmaceutical Sciences Laboratory (Pharmacy), Åbo Akademi University, Tykistökatu 6 A, Biocity, FI-20520 Turku, Finland; ida.alanko@abo.fi (I.A.); rajendra.bhadane@abo.fi (R.B.); parthiban.marimuthu@abo.fi (P.M.); atefeh.saadabadi@abo.fi (A.S.) 2 Structural Bioinformatics Laboratory (Biochemistry), Åbo Akademi University, Tykistökatu 6 A, Biocity, FI-20520 Turku, Finland 3 Faculty of Science-Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, 3584 CH Utrecht, The Netherlands; [email protected] 4 Swedish Drug Delivery Forum (SDDF), Department of Pharmacy, Uppsala Biomedical Center, Uppsala University, 751 23 Uppsala, Sweden; [email protected] (S.H.); [email protected] (A.K.) 5 Biocenter Oulu & Faculty of Biochemistry and Molecular Medicine, University of Oulu, Aapistie 7 A, FI-90014 Oulu, Finland; andre.juffer@oulu.fi 6 School of Pharmacy, University of Eastern Finland, FI-70210 Kuopio, Finland; maija.lahtela-kakkonen@uef.fi (M.L.-K.); tatu.pantsar@uef.fi
    [Show full text]
  • Steven, Stacy (2012) the Pharmacology of the 5-HT2A Receptor and the Difficulty Surrounding Single Taret Models
    Steven, Stacy (2012) The pharmacology of the 5-HT2A receptor and the difficulty surrounding single taret models. MSc(R) thesis. http://theses.gla.ac.uk/3636/ Copyright and moral rights for this thesis are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Glasgow Theses Service http://theses.gla.ac.uk/ [email protected] The pharmacology of the 5-HT2A receptor and the difficulty surrounding functional studies with single target models A thesis presented for the degree of Master of Science by research Stacy Steven April 2012 Treatment of many disorders can be frequently problematic due to the relatively non selective nature of many drugs available on the market. Symptoms can be complex and expansive, often leading to symptoms representing other disorders in addition to the primary reason for treatment. In particular mental health disorders fall prey to this situation. Targeting treatment can be difficult due to the implication of receptors in more than one disorder, and more than one receptor in a single disorder. In the instance of GPCRs, receptors such as the serotonin receptors (and in particular the 5-HT2A for the interest of this research) belong to a large family of receptors, the GPCR Class A super family.
    [Show full text]
  • Selective Labeling of Serotonin Receptors Byd-[3H]Lysergic Acid
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 5783-5787, December 1978 Biochemistry Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate (ergots/hallucinogens/tryptamines/norepinephrine/dopamine) PATRICIA M. WHITAKER AND PHILIP SEEMAN* Department of Pharmacology, University of Toronto, Toronto, Canada M5S 1A8 Communicated by Philip Siekevltz, August 18,1978 ABSTRACT Since it was known that d-lysergic acid di- The objective in this present study was to improve the se- ethylamide (LSD) affected catecholaminergic as well as sero- lectivity of [3H]LSD for serotonin receptors, concomitantly toninergic neurons, the objective in this study was to enhance using other drugs to block a-adrenergic and dopamine receptors the selectivity of [3HJISD binding to serotonin receptors in vitro by using crude homogenates of calf caudate. In the presence of (cf. refs. 36-38). We then compared the potencies of various a combination of 50 nM each of phentolamine (adde to pre- drugs on this selective [3H]LSD binding and compared these clude the binding of [3HJLSD to a-adrenoceptors), apmo ie, data to those for the high-affinity binding of [3H]serotonin and spiperone (added to preclude the binding of [3H[LSD to (39). dopamine receptors), it was found by Scatchard analysis that the total number of 3H sites went down to 300 fmol/mg, compared to 1100 fmol/mg in the absence of the catechol- METHODS amine-blocking drugs. The IC50 values (concentrations to inhibit Preparation of Membranes. Calf brains were obtained fresh binding by 50%) for various drugs were tested on the binding of [3HLSD in the presence of 50 nM each of apomorphine (A), from the Canada Packers Hunisett plant (Toronto).
    [Show full text]
  • Preorganization of Molecular Binding Sites in Designed Diiron Proteins
    Preorganization of molecular binding sites in designed diiron proteins Ornella Maglio*, Flavia Nastri*, Vincenzo Pavone*, Angela Lombardi*†, and William F. DeGrado†‡ *Department of Chemistry, University of Napoli Federico II, Complesso Universitario Monte S. Angelo, I-80126 Napoli, Italy; and ‡Department of Biochemistry and Biophysics, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6059 Contributed by William F. DeGrado, February 6, 2003 De novo protein design provides an attractive approach to criti- (Dueferri 1) (7–10). This protein is a small, 48-residue ho- cally test the features that are required for metalloprotein struc- modimeric model for the family of O2-using diiron proteins ture and function. Previously we designed and crystallographi- that includes methane monooxygenase and the radical-form- cally characterized an idealized dimeric model for the four-helix ing R2 subunit of the ribonucleotide reductase from Esche- bundle class of diiron and dimanganese proteins [Dueferri 1 richia coli (11–14). The DF1 dimer comprises two nonco- (DF1)]. Although the protein bound metal ions in the expected valently associated helix–loop–helix motifs that bind the manner, access to its active site was blocked by large bulky hy- diiron cofactor near the center of the protein (8). The crystal- drophobic residues. Subsequently, a substrate-access channel lographic structures of di-Zn(II) (8) and di-Mn(II) DF1 (un- was introduced proximal to the metal-binding center, resulting published results) are very similar to the di-Mn(II) and di- in a protein with properties more closely resembling those of Fe(II) forms of other natural diiron proteins (15–18).
    [Show full text]
  • Antipsychotics (Part-4) FLUOROBUTYROPHENONES
    Antipsychotics (Part-4) FLUOROBUTYROPHENONES The fluorobutyrophenones belong to a much-studied class of compounds, with many compounds possessing high antipsychotic activity. They were obtained by structure variation of the analgesic drug meperidine by substitution of the N-methyl by butyrophenone moiety to produce the butyrophenone analogue which has similar activity as chlorpromazine. COOC2H5 N H3C Meperidine COOC2H5 N O Butyrophenone analog The structural requirements for antipsychotic activity in the group are well worked out. General features are expressed in the following structure. F AR Y O N • Optimal activity is seen when with an aromatic with p-fluoro substituent • When CO is attached with p-fluoroaryl gives optimal activity is seen, although other groups, C(H)OH and aryl, also give good activity. • When 3 carbons distance separates the CO from cyclic N gives optimal activity. • The aliphatic amino nitrogen is required, and highest activity is seen when it is incorporated into a cyclic form. • AR is an aromatic ring and is needed. It should be attached directly to the 4-position or occasionally separated from it by one intervening atom. • The Y group can vary and assist activity. An example is the hydroxyl group of haloperidol. The empirical SARs suggest that the 4-aryl piperidino moiety is superimposable on the 2-- phenylethylamino moiety of dopamine and, accordingly, could promote affinity for D2 receptors. The long N-alkyl substituent could help promote affinity and produce antagonistic activity. Some members of the class are extremely potent antipsychotic agents and D2 receptor antagonists. The EPS are extremely marked in some members of this class, which may, in part, be due to a potent DA block in the striatum and almost no compensatory striatal anticholinergic block.
    [Show full text]
  • Characterisation, Localisation and Expression of Porcine TACR1, TACR2 and TACR3 Genes
    Veterinarni Medicina, 62, 2017 (08): 443–455 Original Paper doi: 10.17221/23/2017-VETMED Characterisation, localisation and expression of porcine TACR1, TACR2 and TACR3 genes A. Jakimiuk*, P. Podlasz, M. Chmielewska-Krzesinska, K. Wasowicz Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland *Corresponding author: [email protected] ABSTRACT: Substance P is involved in many physiological and pathophysiological processes. This functional diversity is mediated by three neurokinin receptor subtypes (NK1R, NK2R and NK3R) encoded by the TACR1, TACR2 and TACR3 genes, respectively. Despite the increasing interest in using pigs (Sus scrofa) to study human disease mechanisms, the sequences of these receptors are still unconfirmed or in the case of the NK1 receptor, not yet even unpredicted. We employed in silico analysis to define the localisation of the porcine tachykinin receptor genes, and to predict the structures and amino acid sequences of the respective proteins. A reverse transcription polymerase chain reaction (RT-PCR) assay was performed to analyse the expression of tachykinin receptor genes in different porcine tissues. The data show that the TACR1 gene is located on chromosome 3, TACR2 on chromo- some 14 and TACR3 on chromosome 8. All three genes encode proteins with structures that incorporate features of G-protein-coupled receptors with sizes of 407, 381 and 464 amino acids, respectively. The receptors display a high degree of similarity to other mammalian neurokinin receptors. The NK1R subtype is expressed in both the central nervous system and peripheral tissues, while NK2R expression seems to be localised mostly to peripheral tissues. The expression of NK3R is found mainly in the central nervous system.
    [Show full text]
  • Tachykinin Receptor 3 Distribution in Human Oral Squamous Cell
    ANTICANCER RESEARCH 36 : 6335-6342 (2016) doi:10.21873/anticanres.11230 Tachykinin Receptor 3 Distribution in Human Oral Squamous Cell Carcinoma KYOICHI OBATA 1, TSUYOSHI SHIMO 1, TATSUO OKUI 1, KENICHI MATSUMOTO 1, HIROYUKI TAKADA 1, KIYOFUMI TAKABATAKE 2, YUKI KUNISADA 1, SOICHIRO IBARAGI 1, HITOSHI NAGATSUKA 2 and AKIRA SASAKI 1 1Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Okayama, Japan; 2Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan Abstract. Background: Tachykinin 3 (TAC3) and its preferred Previously, the expression of TACR3 was considered to be tachykinin receptor 3 (TACR3) that are prominently detected restricted to the central nervous system, including the cortex, in the central nervous system, play significant roles in nuclei of the amygdala, hippocampus and midbrain (5, 6). physiological development and specifically in the human TAC3 and TACR3 modulate the GnRH release at the reproductive system. The roles of TAC3/TACR3 in oral hypothalamic-pituitary axis (7, 8) and their participation in squamous cell carcinoma are unknown. Materials and the human reproduction system is clear from the fact that Methods: We examined the expression pattern of TAC3/TACR3 mutations of TAC3 and TACR3 are associated with human in clinically-resected oral squamous cell carcinoma samples normosmic hypogonadotropic hypogonadism, a disease using immunohistochemistry and immunofluorescence analysis. characterized by the failure of sexual maturation, impaired Results: We found that even though the expression level of gametogenesis and infertility (9, 10). TAC3 is indispensable TACR3 was negative in the normal epithelium, it was highly to physiological development and human reproductive system elevated in tumor cells.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • Hypothalamic Regulation of Food Intake During Cancer
    Hypothalamic regulation of food intake during cancer Jvalini Dwarkasing Thesis committee Promotor Prof. Dr R.F. Witkamp Professor of Nutrition and Pharmacology Wageningen University Co-promotors Dr K. van Norren Assistant professor, Division of Human Nutrition Wageningen University Dr M.V. Boekschoten Staff scientist, Division of Human Nutrition Wageningen University Other members Prof. Dr J. Mercer, University of Aberdeen, UK Prof. Dr D. Chen, Norwegian university of science and technology, Trondheim, Norway Prof. Dr E. Kampman, Wageningen University Prof. Dr J. Keijer, Wageningen University This research was conducted under the auspices of the Graduate School VLAG (Ad- vanced studies in Food Technology, Agrobiotechnology, Nutrition and Health Sciences). Hypothalamic regulation of food intake during cancer Jvalini Dwarkasing Thesis submitted in fulfilment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. Dr A.P.J. Mol, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Wednesday 11 November 2015 at 4 p.m. in the Aula. Jvalini Dwarkasing Hypothalamic regulation of food intake during cancer 148 pages PhD thesis, Wageningen University, Wageningen, NL (2015) With references, with summaries in Dutch and English ISBN 978-94-6257-548-6 Summary Appetite is often reduced in patients with chronic illness, including cancer. Cancer anorexia, loss of appetite, frequently co-exists with cachexia, and the combined clinical picture is known as anorexia-cachexia syndrome. In patients suffering from this syndrome, anorexia considerably contributes to the progression of cachexia, and strongly impinges on quality of life. Inflammatory processes in the hypothalamus are considered to play a crucial role in the development of disease-related anorexia.
    [Show full text]
  • Antibiotic Resistance: Bioinformatics-Based Understanding As a Functional Strategy for Drug Cite This: RSC Adv., 2020, 10, 18451 Design
    RSC Advances View Article Online REVIEW View Journal | View Issue Antibiotic resistance: bioinformatics-based understanding as a functional strategy for drug Cite this: RSC Adv., 2020, 10, 18451 design Umar Ndagi, *a Abubakar A. Falaki,b Maryam Abdullahi,c Monsurat M. Lawald and Mahmoud E. Soliman e The use of antibiotics to manage infectious diseases dates back to ancient civilization, but the lack of a clear distinction between the therapeutic and toxic dose has been a major challenge. This precipitates the notion that antibiotic resistance was from time immemorial, principally because of a lack of adequate knowledge of therapeutic doses and continuous exposure of these bacteria to suboptimal plasma concentration of antibiotics. With the discovery of penicillin by Alexander Fleming in 1924, a milestone in bacterial infections' treatment was achieved. This forms the foundation for the modern era of antibiotic drugs. Antibiotics such as penicillins, cephalosporins, quinolones, tetracycline, macrolides, sulphonamides, Creative Commons Attribution-NonCommercial 3.0 Unported Licence. aminoglycosides and glycopeptides are the mainstay in managing severe bacterial infections, but resistant strains of bacteria have emerged and hampered the progress of research in this field. Recently, new approaches to research involving bacteria resistance to antibiotics have appeared; these involve combining the molecular understanding of bacteria systems with the knowledge of bioinformatics. Consequently, many molecules have been developed to curb resistance associated with different bacterial infections. However, because of increased emphasis on the clinical relevance of antibiotics, the Received 15th February 2020 synergy between in silico study and in vivo study is well cemented and this facilitates the discovery of Accepted 1st May 2020 potent antibiotics.
    [Show full text]
  • Pharmacology Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200603 PHARMACOLOGY REVIEW(S) Tertiary Pharmacology/Toxicology Review From: Paul C. Brown, Ph.D., ODE Associate Director for Pharmacology and Toxicology, OND IO NDA: 200603 Agency receipt date: 12/30/2009 Drug: Lurasidone hydrochloride Applicant: Sunovion Pharmaceuticals (Originally submitted by Dainippon Sumimoto Pharma America, Inc.) Indication: schizophrenia Reviewing Division: Division of Psychiatry Products Background: The pharm/tox reviewer and team leader concluded that the nonclinical data support approval of lurasidone for the indication listed above. Reproductive and Developmental Toxicity: Reproductive and developmental toxicity studies in rats and rabbits revealed no evidence of teratogenicity or embryofetal toxicity. The high doses in the rat and rabbit embryofetal toxicity studies were 3 and 12 times, respectively, the maximum recommended human dose (80 mg) based on a body surface area comparison. Carcinogenicity: Lurasidone was tested in 2 year rat and mouse carcinogenicity studies. These studies were reviewed by the division and the executive carcinogenicity assessment committee. The committee concluded that the studies were adequate and that there was a drug-related increase in mammary carcinomas in female rats at doses of 12 mg/kg and higher and a drug-related increase in mammary carcinomas and adenoacanthomas and pituitary pars distalis adenomas in female mice. The applicant also provided data from various studies showing that lurasidone significantly increases prolactin in several different species including rats and mice. Conclusions: I agree with the division pharm/tox conclusion that this application can be approved from a pharm/tox perspective. The division recommends that lurasidone be labeled with pregnancy category B.
    [Show full text]